FOXD2 Antibody
-
中文名稱：FOXD2兔多克隆抗體
-
貨號：CSB-PA123895
-
規格：￥1100
-
圖片：
-
The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using CSB-PA123895(FOXD2 Antibody) at dilution 1/10, on the right is treated with synthetic peptide. (Original magnification: ×200)
-
-
其他：
產品詳情
-
Uniprot No.：
-
基因名：FOXD2
-
別名：Drosphilia Forkhead Homolog Like 17 antibody; FKHL 17 antibody; Forkhead box protein D2 antibody; Forkhead Related Activator 9 antibody; Forkhead-related protein FKHL17 antibody; Forkhead-related transcription factor 9 antibody; FOXD2 antibody; FOXD2_HUMAN antibody; FREAC 9 antibody; FREAC-9 antibody
-
宿主：Rabbit
-
反應種屬：Human,Mouse
-
免疫原：Synthetic peptide of Human FOXD2
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Non-conjugated
-
抗體亞型：IgG
-
純化方式：Antigen affinity purification
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
-
產品提供形式：Liquid
-
應用范圍：ELISA,IHC
-
推薦稀釋比：
Application Recommended Dilution ELISA 1:1000-1:2000 IHC 1:15-1:50 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Probable transcription factor involved in embryogenesis and somatogenesis.
-
基因功能參考文獻：
- identified transcription factors FOXD2 and GABP that bind to specific elements in the promoter of the RhitH gene PMID: 22306510
- FOXD2 is a physiological regulator which increases cAMP sensitivity and sets the threshold for cAMP-mediated negative modulation of T cell activation PMID: 12621056
-
亞細胞定位：Nucleus.
-
組織特異性：Kidney specific.
-
數據庫鏈接：
Most popular with customers
-
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
